Draft Approaches for Addressing Training and Experience Requirements for Radiopharmaceuticals Requiring a Written Directive, 23812-23813 [2019-10760]

Download as PDF 23812 Federal Register / Vol. 84, No. 100 / Thursday, May 23, 2019 / Notices khammond on DSKBBV9HB2PROD with NOTICES 3. Routine activities undertaken by NEH to support its program partners, such as serving on task forces, ad hoc committees or representing NEH interests in other forums. 4. Approving and issuing financial assistance to support research, education, preservation, and public programs in the humanities, except where such assistance supports the construction, restoration, or renovation of facilities, including the purchase or lease of new infrastructure, or otherwise involves ground disturbing activity. 5. Approving and issuing financial assistance to support facility planning and design. 6. Approving and issuing grants to support the purchase or lease of preexisting infrastructure. 7. Nondestructive data collection, inventory, study, research, and monitoring activities. B. Program Specific Categorical Exclusions Actions consistent with any of the following categories are, in the absence of extraordinary circumstances, categorically excluded from further analysis and documentation in an EA or EIS. A categorical exclusion determination may only be made after NEH has, if necessary, performed a review under Section 106 of the National Historic Preservation Act (‘‘NHPA’’) and determined and documented that such action is not reasonably likely to have an adverse effect on historic properties. 1. Upgrade, repair, maintenance, replacement, or minor renovations and additions to facilities, grounds and equipment, including but not limited to, roof replacement, foundation repair, access ramp and door improvements pursuant to the Americans with Disabilities Act (‘‘ADA’’), weatherization and energy efficiency related improvements, HVAC renovations, painting, floor system replacement, repaving parking lots and ground maintenance, that do not result in a change in the functional use of the real property. 2. Construction, purchase or lease of new infrastructure, including, but not limited to, museums, libraries and other community buildings, and office space, that is similar to existing land use if the area to be disturbed has no more than two acres of new surface disturbance. The following conditions must be met: a. The structure and proposed use are compatible with applicable Federal, tribal, state, and local planning and zoning standards. b. The site and scale of the construction or improvement is VerDate Sep<11>2014 16:40 May 22, 2019 Jkt 247001 consistent with those of existing, adjacent, or nearby buildings. c. The proposed use will not substantially increase the number of motor vehicles at the facility or in the area. d. The construction or improvement will not result in uses that exceed existing support infrastructure capacities (road, sewer, water, parking, etc.). 3. Construction, purchase or lease of new infrastructure, including, but not limited to, museums, libraries and other community buildings, and office space, where such construction, purchase or lease is for infrastructure of less than 12,000 square feet of useable space. 4. Demolition, disposal, or improvements involving buildings or structures when done in accordance with applicable regulations, including those regulations applying to removal of asbestos, polychlorinated biphenyls (PCBs), and other hazardous materials. [FR Doc. 2019–10745 Filed 5–22–19; 8:45 am] BILLING CODE 7536–01–P NUCLEAR REGULATORY COMMISSION I. Obtaining Information and Submitting Comments [NRC–2018–0230] Draft Approaches for Addressing Training and Experience Requirements for Radiopharmaceuticals Requiring a Written Directive Nuclear Regulatory Commission. ACTION: Request for comment; extension of comment period. AGENCY: On May 2, 2019, the U.S. Nuclear Regulatory Commission (NRC) requested comments on draft approaches regarding the training and experience (T&E) requirements for radiopharmaceuticals requiring a written directive. The public comment period was originally scheduled to close on June 3, 2019. The NRC is extending the comment period to July 3, 2019, to allow more time for stakeholders and members of the public to submit their comments. DATES: The due date of comments requested in the notice published on May 2, 2019 (84 FR 18874) is extended. Comments should be submitted no later than July 3, 2019. Comments received after this date will be considered if it is practical to do so, but the NRC is only able to ensure consideration for comments received on or before this date. ADDRESSES: You may submit comments by any of the following methods: SUMMARY: PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2018–0230. Address questions about NRC docket IDs in regulations.gov to Jennifer Borges; telephone: 301–287–9127; email: Jennifer.Borges@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • Mail comments to: Office of Administration, Mail Stop: TWFN–7– A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001, ATTN: Program Management, Announcements and Editing Staff. For additional direction on obtaining information and submitting comments, see ‘‘Obtaining Information and Submitting Comments’’ in the SUPPLEMENTARY INFORMATION section of this document. FOR FURTHER INFORMATION CONTACT: Sarah Lopas, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415– 6360, email: Sarah.Lopas@nrc.gov. SUPPLEMENTARY INFORMATION: A. Obtaining Information Please refer to Docket ID NRC–2018– 0230 when contacting the NRC about the availability of information for this action. You may obtain publiclyavailable information related to this action by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2018–0230. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301– 415–4737, or by email to pdr.resource@ nrc.gov. The ADAMS accession number for each document referenced is provided the first time that it is mentioned in the SUPPLEMENTARY INFORMATION section. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. B. Submitting Comments Please include Docket ID NRC–2018– 0230 in your comment submission. The E:\FR\FM\23MYN1.SGM 23MYN1 Federal Register / Vol. 84, No. 100 / Thursday, May 23, 2019 / Notices NRC cautions you not to include identifying or contact information in comment submissions that you do not want to be publicly disclosed in your comment submission. All comment submissions are posted at https:// www.regulations.gov and entered into ADAMS. Comment submissions are not routinely edited to remove identifying or contact information. If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment into ADAMS. II. Discussion khammond on DSKBBV9HB2PROD with NOTICES On May 2, 2019, the NRC published a notice in the Federal Register (84 FR 18874) requesting comments on draft approaches the staff developed regarding the T&E requirements for radiopharmaceuticals requiring a written directive. The public comment period was originally scheduled to close on June 3, 2019. By letter dated May 13, 2019 (ADAMS Accession No. ML19136A236), the American College of Radiology, the American Society for Radiation Oncology, and the Society of Nuclear Medicine and Molecular Imaging jointly requested a 30-day extension to the public comment period. United Pharmacy Partners, Inc. also submitted a request for extension by letter dated May 14, 2019 (ADAMS Accession No. ML19136A238). Additional requests for an extension to the public comment period were also heard during a May 14, 2019, public comment meeting. The NRC is granting this request and will extend the public comment period until July 3, 2019, to allow more time for medical and regulatory stakeholders and members of the public to submit their comments. Dated at Rockville, Maryland, this 17th day of May 2019. For the Nuclear Regulatory Commission. Andrea L. Kock, Director, Division of Materials Safety, Security, State, and Tribal Programs, Office of Nuclear Material Safety and Safeguards. [FR Doc. 2019–10760 Filed 5–22–19; 8:45 am] BILLING CODE 7590–01–P VerDate Sep<11>2014 16:40 May 22, 2019 Jkt 247001 POSTAL REGULATORY COMMISSION [Docket Nos. MC2019–138 and CP2019–152; MC2019–139 and CP2019–153; MC2019–140 and CP2019–154] New Postal Product Postal Regulatory Commission. Notice. AGENCY: ACTION: The Commission is noticing a recent Postal Service filing for the Commission’s consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps. DATES: Comments are due: May 28, 2019. SUMMARY: Submit comments electronically via the Commission’s Filing Online system at https:// www.prc.gov. Those who cannot submit comments electronically should contact the person identified in the FOR FURTHER INFORMATION CONTACT section by telephone for advice on filing alternatives. ADDRESSES: FOR FURTHER INFORMATION CONTACT: David A. Trissell, General Counsel, at 202–789–6820. SUPPLEMENTARY INFORMATION: Table of Contents I. Introduction II. Docketed Proceeding(s) I. Introduction The Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to negotiated service agreement(s). The request(s) may propose the addition or removal of a negotiated service agreement from the market dominant or the competitive product list, or the modification of an existing product currently appearing on the market dominant or the competitive product list. Section II identifies the docket number(s) associated with each Postal Service request, the title of each Postal Service request, the request’s acceptance date, and the authority cited by the Postal Service for each request. For each request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 (Public Representative). Section II also establishes comment deadline(s) pertaining to each request. The public portions of the Postal Service’s request(s) can be accessed via the Commission’s website (https:// www.prc.gov). Non-public portions of the Postal Service’s request(s), if any, PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 23813 can be accessed through compliance with the requirements of 39 CFR 3007.301.1 The Commission invites comments on whether the Postal Service’s request(s) in the captioned docket(s) are consistent with the policies of title 39. For request(s) that the Postal Service states concern market dominant product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3622, 39 U.S.C. 3642, 39 CFR part 3010, and 39 CFR part 3020, subpart B. For request(s) that the Postal Service states concern competitive product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3015, and 39 CFR part 3020, subpart B. Comment deadline(s) for each request appear in section II. II. Docketed Proceeding(s) 1. Docket No(s).: MC2019–138 and CP2019–152; Filing Title: USPS Request to Add Priority Mail Contract 528 to Competitive Product List and Notice of Filing Materials Under Seal; Filing Acceptance Date: May 17, 2019; Filing Authority: 39 U.S.C. 3642, 39 CFR 3020.30 et seq., and 39 CFR 3015.5; Public Representative: Kenneth R. Moeller; Comments Due: May 28, 2019. 2. Docket No(s).: MC2019–139 and CP2019–153; Filing Title: USPS Request to Add Priority Mail Express, Priority Mail & First-Class Package Service Contract 62 to Competitive Product List and Notice of Filing Materials Under Seal; Filing Acceptance Date: May 17, 2019; Filing Authority: 39 U.S.C. 3642, 39 CFR 3020.30 et seq., and 39 CFR 3015.5; Public Representative: Kenneth R. Moeller; Comments Due: May 28, 2019. 3. Docket No(s).: MC2019–140 and CP2019–154; Filing Title: USPS Request to Add Priority Mail & First-Class Package Service Contract 100 to Competitive Product List and Notice of Filing Materials Under Seal; Filing Acceptance Date: May 17, 2019; Filing Authority: 39 U.S.C. 3642, 39 CFR 3020.30 et seq., and 39 CFR 3015.5; Public Representative: Kenneth R. Moeller; Comments Due: May 28, 2019. This Notice will be published in the Federal Register. Stacy L. Ruble, Secretary. [FR Doc. 2019–10822 Filed 5–22–19; 8:45 am] BILLING CODE 7710–FW–P 1 See Docket No. RM2018–3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19–22 (Order No. 4679). E:\FR\FM\23MYN1.SGM 23MYN1

Agencies

NUCLEAR REGULATORY COMMISSION

[Federal Register Volume 84, Number 100 (Thursday, May 23, 2019)]
[Notices]
[Pages 23812-23813]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10760]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[NRC-2018-0230]


Draft Approaches for Addressing Training and Experience 
Requirements for Radiopharmaceuticals Requiring a Written Directive

AGENCY: Nuclear Regulatory Commission.

ACTION: Request for comment; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: On May 2, 2019, the U.S. Nuclear Regulatory Commission (NRC) 
requested comments on draft approaches regarding the training and 
experience (T&E) requirements for radiopharmaceuticals requiring a 
written directive. The public comment period was originally scheduled 
to close on June 3, 2019. The NRC is extending the comment period to 
July 3, 2019, to allow more time for stakeholders and members of the 
public to submit their comments.

DATES: The due date of comments requested in the notice published on 
May 2, 2019 (84 FR 18874) is extended. Comments should be submitted no 
later than July 3, 2019. Comments received after this date will be 
considered if it is practical to do so, but the NRC is only able to 
ensure consideration for comments received on or before this date.

ADDRESSES: You may submit comments by any of the following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC-2018-0230. Address 
questions about NRC docket IDs in regulations.gov to Jennifer Borges; 
telephone: 301-287-9127; email: [email protected]. For technical 
questions, contact the individual listed in the FOR FURTHER INFORMATION 
CONTACT section of this document.
     Mail comments to: Office of Administration, Mail Stop: 
TWFN-7-A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-
0001, ATTN: Program Management, Announcements and Editing Staff.
    For additional direction on obtaining information and submitting 
comments, see ``Obtaining Information and Submitting Comments'' in the 
SUPPLEMENTARY INFORMATION section of this document.

FOR FURTHER INFORMATION CONTACT: Sarah Lopas, Office of Nuclear 
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555-0001; telephone: 301-415-6360, email: 
[email protected].

SUPPLEMENTARY INFORMATION: 

I. Obtaining Information and Submitting Comments

A. Obtaining Information

    Please refer to Docket ID NRC-2018-0230 when contacting the NRC 
about the availability of information for this action. You may obtain 
publicly-available information related to this action by any of the 
following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC-2018-0230.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS 
Search.'' For problems with ADAMS, please contact the NRC's Public 
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or 
by email to [email protected]. The ADAMS accession number for each 
document referenced is provided the first time that it is mentioned in 
the SUPPLEMENTARY INFORMATION section.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.

B. Submitting Comments

    Please include Docket ID NRC-2018-0230 in your comment submission. 
The

[[Page 23813]]

NRC cautions you not to include identifying or contact information in 
comment submissions that you do not want to be publicly disclosed in 
your comment submission. All comment submissions are posted at https://www.regulations.gov and entered into ADAMS. Comment submissions are not 
routinely edited to remove identifying or contact information.
    If you are requesting or aggregating comments from other persons 
for submission to the NRC, then you should inform those persons not to 
include identifying or contact information that they do not want to be 
publicly disclosed in their comment submission. Your request should 
state that the NRC does not routinely edit comment submissions to 
remove such information before making the comment submissions available 
to the public or entering the comment into ADAMS.

II. Discussion

    On May 2, 2019, the NRC published a notice in the Federal Register 
(84 FR 18874) requesting comments on draft approaches the staff 
developed regarding the T&E requirements for radiopharmaceuticals 
requiring a written directive. The public comment period was originally 
scheduled to close on June 3, 2019. By letter dated May 13, 2019 (ADAMS 
Accession No. ML19136A236), the American College of Radiology, the 
American Society for Radiation Oncology, and the Society of Nuclear 
Medicine and Molecular Imaging jointly requested a 30-day extension to 
the public comment period. United Pharmacy Partners, Inc. also 
submitted a request for extension by letter dated May 14, 2019 (ADAMS 
Accession No. ML19136A238). Additional requests for an extension to the 
public comment period were also heard during a May 14, 2019, public 
comment meeting. The NRC is granting this request and will extend the 
public comment period until July 3, 2019, to allow more time for 
medical and regulatory stakeholders and members of the public to submit 
their comments.

    Dated at Rockville, Maryland, this 17th day of May 2019.

    For the Nuclear Regulatory Commission.
Andrea L. Kock,
Director, Division of Materials Safety, Security, State, and Tribal 
Programs, Office of Nuclear Material Safety and Safeguards.
[FR Doc. 2019-10760 Filed 5-22-19; 8:45 am]
 BILLING CODE 7590-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.